We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Evidence to Practice |

Amyloid-β Positron Emission Tomography in the Diagnostic Evaluation of Alzheimer Disease Summary of Primary Findings and Conclusions

Steven D. Pearson, MD, MSc1; Daniel A. Ollendorf, MPH, ARM1; Jennifer A. Colby, PharmD1
[+] Author Affiliations
1The Institute for Clinical and Economic Review, Boston, Massachusetts
JAMA Intern Med. 2014;174(1):133-134. doi:10.1001/jamainternmed.2013.11711.
Text Size: A A A
Published online


The only definitive method for diagnosing Alzheimer disease (AD) has been a combination of clinical diagnosis and findings of pathognomonic amyloid-β (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated forms of the protein tau on examination of the brain at autopsy. In April 2012, however, the Food and Drug Administration approved Aβ positron emission tomography (PET) with florbetapir F-18 (Amyvid; Lilly USA) to identify areas of accumulation of Aβ plaques.1 The label for florbetapir F-18 states that a negative scan result indicates a reduced likelihood that any cognitive impairment is due to AD, but that a positive scan result does not establish a diagnosis of Alzheimer or any other neurodegenerative disease because excess Aβ is also found in adults with normal cognition. Although this review assessed the evidence for all purported diagnostic tests for AD, it focused on the evidence related to Aβ PET scans.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

4 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles